Thornton K L, DeFronzo R A, Sherwin R S, Diamond M P
Yale University School of Medicine, New Haven, Connecticut, USA.
J Soc Gynecol Investig. 1995 Jul-Aug;2(4):643-52. doi: 10.1016/1071-5576(95)00012-4.
We assessed glucose utilization and insulin sensitivity in normal reproductive-age women after administration of micronized estradiol, micronized progesterone, or the combination of micronized estradiol and progesterone.
Hyperglycemic and euglycemic, hyperinsulinemic clamp studies were performed in normal, regularly cycling women both before and after a short course of either micronized estradiol (n = 8), micronized progesterone (n = 8), or micronized estradiol and progesterone (n = 7). All studies were performed after an overnight fast. Glucose and insulin were determined in the control period and then every 2-10 minutes in the hyperglycemic clamp studies and every 5-10 minutes in the euglycemic clamp studies. In the hyperglycemic clamp studies, hyperglycemia was maintained by a variable glucose infusion. In the euglycemic clamp studies, a primed 3-3H glucose infusion (25 microCi) followed by a 0.25-microCi continuous infusion was begun 120 minutes before initiation of the insulin infusion and variable glucose infusion. Samples for glucose radioactivity were measured during the control period and during the last 40 minutes of each step of the euglycemic clamp after establishment of a steady state.
No differences in baseline glucose or insulin levels were detected in any of the study groups as compared with control. Glucose utilization as assessed by the hyperglycemic clamp model was not significantly different from control in the estradiol group, the progesterone group, or the group treated with the combination. In all of the treatment groups, no significant differences were noted under euglycemic, hyperinsulinemic conditions in glucose utilization, hepatic glucose production, or insulin sensitivity.
Women of reproductive age do not demonstrate significant differences in basal levels of glucose or insulin when given a short course of micronized estradiol and progesterone, either alone or in combination. Under conditions of the hyperglycemic, hyperinsulinemic clamp, the pancreatic beta-cell response to hyperglycemia and glucose utilization is not significantly altered by exogenous administration of hormones. Conditions of the euglycemic, hyperinsulinemic clamp failed to elicit significant differences in glucose utilization and insulin sensitivity in any of the three treatment groups. These findings demonstrate that glucose homeostasis is not altered by the exogenous administration of natural hormones in reproductive-age women.
我们评估了微粒化雌二醇、微粒化孕酮或微粒化雌二醇与孕酮联合用药后,正常育龄女性的葡萄糖利用情况和胰岛素敏感性。
对正常、月经周期规律的女性,在短期给予微粒化雌二醇(n = 8)、微粒化孕酮(n = 8)或微粒化雌二醇与孕酮联合用药(n = 7)前后,进行高血糖和正常血糖、高胰岛素钳夹试验。所有试验均在过夜禁食后进行。在对照期测定葡萄糖和胰岛素水平,然后在高血糖钳夹试验中每2 - 10分钟测定一次,在正常血糖钳夹试验中每5 - 10分钟测定一次。在高血糖钳夹试验中,通过可变葡萄糖输注维持高血糖状态。在正常血糖钳夹试验中,在开始胰岛素输注和可变葡萄糖输注前120分钟,开始给予一次3 - 3H葡萄糖预充液(25微居里),随后进行0.25微居里的持续输注。在对照期以及正常血糖钳夹试验达到稳态后的每个步骤的最后40分钟,测量葡萄糖放射性样本。
与对照组相比,任何研究组的基线葡萄糖或胰岛素水平均未检测到差异。通过高血糖钳夹模型评估的葡萄糖利用情况,在雌二醇组、孕酮组或联合用药组与对照组之间无显著差异。在所有治疗组中,在正常血糖、高胰岛素条件下,葡萄糖利用、肝葡萄糖生成或胰岛素敏感性均未观察到显著差异。
育龄女性在短期给予微粒化雌二醇和孕酮单独或联合用药时,基础葡萄糖或胰岛素水平无显著差异。在高血糖、高胰岛素钳夹条件下,外源性给予激素不会显著改变胰腺β细胞对高血糖的反应和葡萄糖利用情况。在正常血糖、高胰岛素钳夹条件下,三个治疗组中的任何一组在葡萄糖利用和胰岛素敏感性方面均未出现显著差异。这些发现表明,外源性给予天然激素不会改变育龄女性的葡萄糖稳态。